Lower IFNL2 was also associated with a more severe clinical outcome in COVID-19 patients (Fig. 3b) with significantly reduced levels in patients with severe disease (WHO 5–8) compared to a milder outcome (WHO 1–2). The gene discussed is IFNL2; the disease is COVID-19.